Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study

Investigational New Drugs

Volumn 17, Issue 1, 1999, Pages 57-61

  Poplin, Elizabeth ^a   Roberts, John ^b   Tombs, Marybeth ^b   Grant, Steven ^b   Rubin, Eric ^b  

^a The Cancer Institute New Jersey   (United States)

^b NONE

Author keywords

Fluorouracil; Gemcitabine; Phase I study

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG TOXICITY; FATIGUE; FEMALE; HUMAN; INFORMED CONSENT; LUNG CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0032849563     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006239200772     Document Type: Article

References (23)

1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. Journal of Clinical Oncology 12(8): 1535-1540, 1994
2. Anderson H, Lund B, Bach F et al.: Single agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1821, 1994
3. Carmichael J, Possinger K, Phillip P et al.: Advanced breast cancer: a phase II trial with gemcitabine. Journal of Clinical Oncology 13: 2731-2736, 1995
4. Burris HA, Moore MJ, Andersen J: Improvement in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer. A randomized study. J Clin Oncol 15: 2403, 1997
5. Casper E, Green M, Kelsen D, Heelan R, Brown T, Flombaum C, Trochanowski B, Tarassoff P: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Investigational New Drugs 12: 29-34, 1994
6. Heinemann V, Xu Yi-Zheng, Chubb, Sherri, Sen, Alina, Hertel, Larry W, Grindey, Gerald B: Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphase: A mechanism of self-potentiation. Cancer Research 52: 533-539, February 1992
7. Plunkett W, Huang P, Xu Y-Z, Heinemann V, Grunewald R and Gandhi V: Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Seminars in Oncology 22: 3-10, 1995
8. Plunkett W, Huang, Peng, Searcy, Catherine E, Gandhi, Varsha: Gemcitabine: preclinical pharmacology and mechanisms of action. Seminars in Oncology 23-5(10): 3-15, 1996
9. Baker CH, Banzon J, Bollinger JM et al.: 2′-deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34: 1879-1984, 1991
10. Heinemann V, Xu Y-Z, Chubb S et al.: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38: 567-572, 1990
11. Armstrong RD: Fluoropyrimidine activity and resistance at the cellular level. In: Kessel (ed), Resistance to Antineoplastic Drugs, CRC Press, 1989
12. Valeriote F and Santelli G: 5-Fluorouracil (FUra). Pharmac Ther 24: 107-32, 1984
13. Moran RG, Danenberg PV, Heidelberger C: Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis. Biochemical Pharmacology 31: 3939-3935, 1982
14. Moran RG, Keyomarsi K: Biochemical rationale for the synergism of 5-fluorouracil and folinic acid. NCI Monographs 5: 159-163, 1987
15. Myers CE: The pharmacology of the fluoropyrimidines. Pharmacological Reviews 33(1): 1-15, Mar. 1981
16. Engstrom PF, MacIntyre JM, Schutt AJ, Douglass Jr. HO: Chemotherapy of large bowel carcinoma - fluorouracil (FU) + hydroxyurea (HU) vs. methyl-CCNU, oncovin, fluorouracil, and streptozotocin (MOF-Strep). American Journal of Clinical Oncology (CCT) 8: 358-361, 1985
17. Kao AK, Muggi FM, Dubin N, Lerner WA, Stark R, Wernz JC, Speyer JL, Blum: Evaluation of a sequential 5-FU and hydroxyurea combination in advanced bowel cancer. Cancer Treatment Reports Vol. 68: 1383-1385, 1984
18. Muggia FM, Moran RG: Treatment of colon cancer based on biochemical modulation of fluoropyrimidines by hydroxyurea. Seminars in Oncology, Vol. 19(3): 90-93, 1992
19. Walsh C, Speyer JL, Wernz JC et al.: Trial based on biochemical modulation of 5-fluorouracil by daily sequential hydroxyurea in colorectal cancer. Proc Am Assoc Cancer Res 26: 168, 1985
20. Vokes EE: Fluorouracil modulation in head and neck cancer. In: Rustum YM (ed), Novel Approaches to Selective Treatments of Human Solid Tumors - Laboratory and Clinical Correlation, Plenum Press, New York 1993
21. Ren Q-F, Grem JL: Synergistic cytotoxicity & induction of parental DNA fragmentation with sequential gemcitabine & 5-fluoro-2′deoxyuridine in HT29 colon cancer cells. National Cancer Institute-Navy Medical Oncology Branch, National Naval Medical Center, Bethesda, MD AACR, Vol 36: 2421, 1995
22. Schulz L, Schalhorn A, Wilmanns W, Heinemann V: Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells. Klinikum Grosshadern, Medical Clinic III, University of Munich, Institute of Hematology, GSF, Munich, Germany. ASCO, Vol. 17: 965, 1998
23. Berlin J, Voi M, Alberti D, Arzoomanian RZ, Feierabend C, Morgan K, Simon K, Hardin J, Wilding G: Phase I trial of gemcitabine, leucovorin and 5-fluorouracil in patients with advanced malignancy. ASCO, Vol. 16, 1997